MIRM - CIK 0001759425
Mirum Pharmaceuticals, Inc. trades as MIRM and has a market capitalization of $5.73 B, making it the #1294 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $521.31M, up 54.7% from the prior year and net income of -$23.36M. This page tracks Mirum Pharmaceuticals, Inc. through 612 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -438.9% to -4.5% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Major company event | 8-K | 2026-05-18 |
| Insider sale notice | 144 | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-05-04 |
| SCHEDULE 13G/A | - | 2026-04-27 |
| Major company event | 8-K | 2026-04-27 |
_\- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)_
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM), a leading rare disease company, today announced its intention to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Mirum also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $90.0 million aggregate principal amount of notes.
The largest companies sharing Mirum Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Mirum Pharmaceuticals, Inc. (MIRM) has a market capitalization of $5.73 B as of 2026-06-10, ranking #1294 among US-listed companies.
Mirum Pharmaceuticals, Inc. reported revenue of $521.31M for fiscal year 2025, an increase of 54.7% year over year.
In its latest fiscal year Mirum Pharmaceuticals, Inc. reported a net loss of $23.36M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will participate in the following upcoming investor conferences:
\- _2026 net product sales guidance increased to $660 to $680 million_